Target intelligence / Profile preview

Endothelial cell adhesion molecule (null)

Target
null
Molecular classification
Immunoglobulin superfamily, Selectins, Cadherins, Integrins
01

Overview

Endothelial cell adhesion molecules are a heterogeneous group of cell-surface proteins primarily expressed on endothelial cells lining blood vessels. These include immunoglobulin superfamily members (e.g., ICAM-1, VCAM-1, PECAM-1), selectins (E-selectin, P-selectin), and cadherins (VE-cadherin), among others[2][4][5][7]. Their main roles are to regulate cell-cell interactions necessary for vascular integrity, control the trafficking of leukocytes during immune surveillance and inflammation, and modulate vascular permeability. Dysregulation or over-expression of these molecules is implicated in diseases such as atherosclerosis, cancer metastasis, and chronic inflammatory conditions. They are attractive therapeutic targets for modulating immune cell recruitment and vascular inflammation, and several drugs and experimental therapeutics target these molecules for the treatment of autoimmune, cardiovascular, and cancer-related pathologies[5][8][9].

Other names
Endothelial adhesion moleculesCAMsendothelial CAMs
02

Mechanism of action

Inhibition of leukocyte adhesion (blocking integrin-VCAM/ICAM interactions). Disruption of endothelial barrier (e.g., anti-VE-cadherin antibodies). Reduction of inflammation by antagonizing selectin-mediated rolling or adhesion of leukocytes.

03

Biological functions

Leukocyte adhesion and transmigration (diapedesis)Maintenance of endothelial barrier function and vascular permeabilityCell-cell junction formation (tight junctions, adherens junctions)Signal transduction affecting inflammation, cytoskeleton, and permeability
04

Disease associations

Inflammation (including atherosclerosis, autoimmune diseases)Cancer (especially metastasis and angiogenesis)Cardiovascular disease (e.g., atherosclerosis)Infection (pathogen entry, immune response modulation)Other (neurological diseases, e.g., breakdown of the blood-brain barrier)
05

Safety considerations

Immunosuppression (increased infection risk)Potential for impaired tissue repair (by inhibiting leukocyte migration and inflammation)Endothelial barrier disruption and possible edema
06

Interacting drugs

Natalizumab

3 more in the full profile.

07

Biomarkers

Soluble ICAM-1 (sICAM-1)Soluble VCAM-1 (sVCAM-1)Soluble E-selectin

Beyond the preview

Go deeper on Endothelial cell adhesion molecule (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endothelial cell adhesion molecule (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call